Capecitabine News and Research RSS Feed - Capecitabine News and Research

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [More]
Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. [More]
Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments. [More]
Eribulin therapy effective in women with metastatic breast cancer

Eribulin therapy effective in women with metastatic breast cancer

An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings today in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen. [More]

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups. [More]
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
Teva launches generic Xeloda Tablets in the U.S.

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States. [More]
Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. [More]
Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. [More]
First generic version of Xeloda gets FDA approval for breast and colorectal cancers

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer. [More]
Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer. [More]
Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer. [More]

Eribulin shows increased benefit among women sharing certain traits

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. [More]
Report: 83% of cancer doctors face oncology drug shortages

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510). [More]
Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

‚ÄčThe U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. [More]
Oxaliplatin and bevacizumab disappoint for rectal cancer

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. [More]
Personalized rectal cancer therapy shows promise

Personalized rectal cancer therapy shows promise

Personalized chemotherapy for rectal cancer results in high rates of pathologic response, indicate the results of a pilot study. [More]

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. [More]
Advertisement
Advertisement